Although many examples of unrelated hemophilia A patients carrying identical point mutations in the factor Vill (FVIII) gene have been reported, the clinical phenotype is not always the same among patients sharing the same molecular defect. Possible explanations for this discrepancy include undetected additional mutations in the FVlll gene or coinheritance of mutations at other genetic loci that modulate FVlll function. We report molecular genetic analysis of potential modifying genes in two sets of unrelated patients carrying common FVlll missense mutations but exhibiting different levels of clinical severity. Both mutations (NI11 R1689C and R2209Q) are associated with severe hemophilia A in some patients and mild/moderate disease in others. The common von Willebrand disease type 2N mutation (R91Q) was excluded as a modifying factor in these groups EMOPHILIA A, an X-linked recessive bleeding disorder, affects approximately 1 in 5,000 males. The disease results from a deficiency of the coagulation protein factor VI11 (FVIII). Molecular genetic studies of hemophilia A patients have identified more than 200 distinct mutations in the FVIII gene.' An intrachromosomal inversion of the FVIII gene resulting in the separation of exons 1 through 22 from exons 23 through 26 has recently been shown to account for the disease in -40% of severe hemophiliacs.'
Although many examples of unrelated hemophilia A patients carrying identical point mutations in the factor Vill (FVIII) gene have been reported, the clinical phenotype is not always the same among patients sharing the same molecular defect. Possible explanations for this discrepancy include undetected additional mutations in the FVlll gene or coinheritance of mutations at other genetic loci that modulate FVlll function. We report molecular genetic analysis of potential modifying genes in two sets of unrelated patients carrying common FVlll missense mutations but exhibiting different levels of clinical severity. Both mutations (NI11 R1689C and R2209Q) are associated with severe hemophilia A in some patients and mild/moderate disease in others. The common von Willebrand disease type 2N mutation (R91Q) was excluded as a modifying factor in these groups EMOPHILIA A, an X-linked recessive bleeding disorder, affects approximately 1 in 5,000 males. The disease results from a deficiency of the coagulation protein factor VI11 (FVIII). Molecular genetic studies of hemophilia A patients have identified more than 200 distinct mutations in the FVIII gene.' An intrachromosomal inversion of the FVIII gene resulting in the separation of exons 1 through 22 from exons 23 through 26 has recently been shown to account for the disease in -40% of severe hemophiliacs. ' Based on the level of measureable FVIII activity, hemophiliacs are classified as severe (< 1 % normal FVIII activity), moderate (1% to 4% W111 activity), or mild (5% to 25% FVIII activity).' The vast majority of mildmoderate hemophiliacs who have been studied have been shown to have a missense mutation in the FVIII gene. Although greater than 80 examples of unrelated hemophilia A patients carrying identical point mutations in the FVIII gene have been reported, the clinical phenotype is variable for some patients sharing the same molecular defect.' For example, although 13 different patients have been identified carrying the same arginine for cysteine substitution at codon 1689,4 are classified as severe hemophilia A with FVIII activity less than 1 % and 9 as mildmoderate hemophilia. Fourteen patients have also been identified who share a substitution of glutamine for arginine at codon 2209, with 9 classified as severe hemophilia A and 5 as mildmoderate disease. ' Possible explanations for this variable expressivity of hemophilia A phenotype among individuals carrying identical FVIII mutations include undetected additional mutations in the FVIII gene, interlaboratory differences in FVIII assays, or the effects of mutations at other loci. Berg et a14 recently described a family in which coinheritance of both factor XI and FVIII deficiencies resulted in a more severe bleeding tendency than that associated with either deficiexy alone. A new subtype of von Willebrand disease (vWD) was recently identified (type 2N vWD) due to defects within the FVIII binding domain of von Willebrand factor (vWF),~-* The gene frequency for the most common type 2N vWD defect (vWF R91Q) may be as high as 1% in some populations.' Although H of patients. However, analysis of the recently described factor V (FV) R5060 mutation (leading t o activated protein c resistance) identified a correlation of inheritance of this defect with reduced hemophilia A severity. Two moderately affected hemophilia A patients, each with either of two FVM gene mutations, were heterozygous for FV R506Q. whereas two severely affected patients and t w o moderately affected patients were homozygous normal at the FV locus. Our results suggest that coinheritance of the FV R5060 mutation may be an important determinant of clinical phenotype in hemophilia A and that modification of the protein C pathway may offer a new strategy for the treatment of FVlll deficiency. 0 1996 by The American Society of Hematology.
these patients generally carry a normal FVIII gene, homozygosity for type 2N vWD results in very low W 1 1 1 activity levels and a phenotype closely resembling hemophilia A. We previously hypothesized that coinheritance of a type 2N vWD allele with hemophilia A might result in a more severe hemophilia phen~type.~ Another potential modifier gene for hemophilia A is the recently described factor V (FV) R506Q mutation associated with activated protein C (APC) resistance and thrombophilia.".'' This mutation is remarkably common, occurring at a frequency of 2% to 7% in a number of populations.'2" 4 We now report molecular genetic analysis of potential modifying genes in two sets of unrelated patients who share a common FVIII missense mutation but have different clinical phenotypes. Our results suggest that coinheritance of the FV R506Q mutation may be an important determinant of clinical phenotype in hemophilia A and that modification of the protein C pathway may offer a new strategy for the treatment of FVIII deficiency.
MATERIALS AND METHODS

Materials.
Normal, FVIII-deficient, and FV-deficient pooled human plasmas were obtained from George King Biomedical, Inc (Overland Park, KS). Monoclonal antibody to the heavy chain of FV111" coupled to CUB-sepharosel' was a gift from Debra Pittman (Genetics Institute, Cambridge, MA). Activated partial thromboplastin (Automated APTT reagent) was purchased from General Diagnostics Organon Teknika Corp (Durham, NC). Wild-type FV (768 pg/mL, 49 UlmL) and FV R5060 (261 PglmL. 14 UlmL) were purified from human plasma and generously supplied by M.J. Heeb and J.H. Griffin (The Scripps Research Institute, La Jolla, CA).
Patients. Mutation identification in all of the patients studied here has been previously reported. Patients H 10'" and JH.38" carry a substitution of cysteine for arginine at codon 1689 (FVIII R1689C). Although patient H10 has severe hemophilia A (undetectable FVlll activity), patient JH38 has only moderate disease (2% to 3% FVlll activity). Patients HP16 and HP17IX have the identical substitution at codon 2209, resulting in a substitution of arginine for glutamine (FVIII R2209Q). Patient HP16 has mild hemophilia A (7% FVlll activity), and patient HP17 has severe disease (< I% FVlll activity). Patients 785 and 818"' also carry the FVlll R2209Q mutation, both with moderate disease (2% to S% FVlll activity).
DNA analvsis for detection of the FV RS06Q mutation. Approximately 200 ng of total genomic DNA was amplified by the polymerase chain reaction (PCR) in a 25 pL reaction using 50 ng each of primers S'-TGCCCAGTGCTTAACAAGACCA-3' and 5'-TGT-TATCACACTGGTGCTAA-3' specific for a 267-bp fragment of the FV gene that includes part of exon 10." PCR conditions were an initial denaturation for 2 minutes at 94°C followed by 1 minute at 94°C. 1 minute at 54°C. and I minute at 72°C for 35 cycles using an MJ Research 96V thermocycler (MJ Research, Inc, Watertown, MA). A final extension for S minutes at 72°C was performed to ensure complete extension of the PCR products. After amplification, 7.5 pL of PCR product was digested with Mnl I (New England Biolabs, Beverly, MA) in a IS pL total reaction volume at 37°C for 1 hour to detect the G to A substitution at bp 1 I 1 responsible for the RS06Q mutation. Digested PCR products were separated by electrophoresis through 4% composite (3% FMC Bioproducts [Rockland, ME] Nusieve and 1% GlBCO BRL [Gaithersburg, MD]) agarose and visualized by staining with ethidium bromide.
DNA analysis for detection of the vWF R9lQ mutation. Detection of the vWF R91Q mutation was performed as previously described.' Briefly, genomic DNA was amplified by PCR using primers specific for exon 20 of the vWF gene. The vWF R91Q mutation was detected by allele-specific oligonucleotide hybridization using specific IS-mers for the normal and mutant alleles.
FVIll assay. FVlll activities were measured in a one-stage clotting assay using FVIII-deficient plasma as a substrate. One unit of FVlll activity is that amount measured in I mL of normal human pooled plasma. To determine whether FV R506Q increases FVllI activity in the clotting assay, FV-deficient plasma containing low levels of FVlIl were reconstituted with wild-type or R506Q FV. FVlll was immunodepleted from I mL of FV-deficient plasma by the addition of 1 0 0 pL of anti-FVIII antibody' coupled to C U Bsepharose and incubation at 4°C overnight. The plasma supernatant was collected after centrifugation. The amount of FVllI activity remaining in the FV-deficient plasma after immunodepletion was 134 mUlmL. A total of 14 UlmL of purified wild-type or R506Q
FV was diluted with the FVIII-depleted FV-deficient plasma to I. 0.5, and 0.25 UlmL. FVlll activity of these samples was determined by the one-stage clottivg assay.
RESULTS
DNA analysis for detection of the FV R506Q mutation is shown in Fig 1. The G to A substitution responsible for the Two other patients with moderate hemophilia A (785 and 8 18) known to carry the FVIII R2209Q mutation are homozygous normal at amino acid 506 of the FV gene (data not shown). Using allele specific oligonucleotide hybridization analysis, none of the patients was shown to carry the vWF R91Q mutation (data not shown).
Patient HP16 was shown to also have a thymine to cytosine substitution at position -601 of the FVIII gene. The
For personal use only. on April 19, 2017. by guest www.bloodjournal.org From effects of this substitution on FVIII gene expression was analyzed using previously described methods." Transient transfection of FVIII promoter sequences containing this substitution linked to a luciferase reporter into liver-derived PLC/PRF/5 cells showed no significant difference from the wild-type promoter. DNase I footprint analysis using rat liver nuclear extracts also showed no significant differences in the J footprint between the wild-type and -601 T+C substituted alleles (data not shown).
The effect of R506Q FV on the measurement of FVIII activity was determined by a one-stage clotting assay after reconstitution of FV-deficient/FVIII-depleted human plasma with increasing amounts of wild-type or R506Q purified plasma-derived FV. As seen in Table 1 , reconstitution with either wild-type or R506Q FV slightly increased FVIII activity. However, there was no difference in the amount of FVIII activity detected in the presence of R506Q FV compared with wild-type FV.
DISCUSSION
Genetic deficiencies in a number of specific clotting factors have been identified in association with inherited bleeding disorders. Phenotypic variability among individuals carving identical genetic mutations has been identified for a large number of genetic diseases, including hemophilia A' and other coagulation and thrombotic Possible explanations for this variable expressivity include the contribution of a second, undetected abnormality in the same gene as well as modifying effects of mutations at other genetic loci. Although an additional substitution was identified in the FVIII promoter of one patient in our study (HP16), this change appears to be a silent variation with no significant effect on FVIII gene expression.
Interaction between coinherited genetic abnormalities have previously been reported for deficiencies of several clotting factors, including FVIII and factor X14,23 as well as factor XI and vWF.'~.'~ The remarkably high general population frequency (2% to 7%)'2"4 of the newly discovered FV R506Q mutation and its association with increased risk for venous thrombosis suggest that it could be a particularly important contributing factor to the variable coagulation responses observed among patients with hemophilia A and other clotting factor deficiencies. This effect was recently shown for the highly variable thrombotic risk associated with protein C deficiency" as well as protein S deficiency."j In an effort to identify genetic loci outside of the FVIII gene that may modify the hemophilia A phenotype, we analyzed the DNA of two sets of unrelated hemophilic patients sharing the same FVIII gene mutations but differing in disease phenotype (severe v mild/moderate). Mutations in the FVIII binding domain of vWF presented a particularly attractive candidate for this analysis. Binding of FVIII to vWF in plasma is required for FVIII stability. Patients with mutations in this region of vWF (type 2N vWD) exhibit decreased plasma FVIII levels, and the frequency of the vWF R91Q mutation may be as high as 1% in some population^.^^^' Although the vWF R91Q mutation was not detected in our current analysis, type 2N vWD should remain an important consideration as a potential modifier of hemophilia A severity.
DNA analysis for the FV R506Q mutation identified this defect in two mild/moderate hemophilia A patients, one with the FVIII R1689C mutation and one with the FVIII R2209Q mutation. In contrast, a severe hemophilia A patient with the FVIII R1689C mutation and one severe and two mild/ moderate hemophilia A patients with the FVIII R2209Q mutation were all homozygous normal (R506) at the FV locus. Although these data suggest that the FV R506Q mutation may be an important modulator of disease severity in a subset of hemophilia A patients, the discrepancy in disease severity for the two patients with the FVIII R2209Q mutation and normal FV R506 suggests that a number of other potential inherited and acquired modifying factors remain to be identified. In contrast to our results, a preliminary study by Chan et a128 failed to detect a clear association between the FV R506Q mutation and the clinical severity of hemophilia A. Also, in a study of 18 hemophilia A patients with FVIII activity less than 1% but a milder bleeding phenotype (mild severe hemophilia A) by Arbini et al,29 none of the 18 was found to carry the FV R506Q mutation. A variable modifying effect of the FV R506Q mutation on hemophilia A severity, dependent on the precise underlying FVIII defect, could explain this discrepancy. The effect of the FV R506Q mutation might be most pronounced in the context of specific FVIII gene mutations, such as the R1689C mutation that occurs at a thrombin cleavage site. More detailed correlation of the clinical course in hemophilia A for different FV and FVIII genotypes should provide a clearer picture of this potential interaction.
The biochemistry of the protein C pathway suggests a plausible mechanism for the attenuation of FVIII deficiencyrelated bleeding by the FV R506Q mutation. APC inactivates activated FV (FVa) by proteolysis first at R506, followed by cleavage at R306 and R679 that results in loss of cofactor activity." Recent studies have shown that FVa R506Q is not completely APC resistant3'"'. FVa from patients lacking the R506 cleavage site is still inactivated after cleavage at R306 and R679. However, the rate of inactivation is much slower than in normal (wild-type) FVa.
Although FV-deficient/FVIII-depleted human plasma reconstituted with FV R506Q had similar FVIII activity as that reconstituted with wild-type FV ( 
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